We know that early menopause, with the associated declines in certain hormones such as estrogen, can result in an increased risk of glaucoma. Now, there is reason to believe that certain postmenopausal hormone therapy (PMH) may actually reduce the risk of glaucoma.
According to researchers publishing in JAMA Ophthalmology taking estrogen only postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG). By reviewing data from 152,163 women 50 years or older the researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG whereas each additional month of use of estrogen + progesterone or estrogen + androgen hormones did not affect risk for POAG. This is interesting information and will require further prospective clinical studies to understand fully but may offer some novel treatments for primary open angle glaucoma (POAG), an insidious sight threatening eye diseases and the most common type of glaucoma.
If you or someone you know has questions or concerns about glaucoma and postmenopausal hormone therapy, please call Doctor & Associates-203-227-4113, visit Doctor & Associates or facebook.com/doctorandassociates to schedule an appointment. Doctor & Associates offices are located at 129 Kings Highway North, Westport, Connecticut 06880, 195 Danbury Road, Wilton, Connecticut 06897 and 148 East Avenue, Norwalk, Connecticut 06851.